Skip to main content
Premium Trial:

Request an Annual Quote

ProNAi Closes $6.65M Financing to Support DNAi Drug Development

NEW YORK (GenomeWeb News) - ProNAi Therapeutics has secured $6.65 million in bridge funding from several financing sources, the company said today.
 
The Kalamazoo, Mich.-based startup uses DNA interference to develop drugs aimed at treating non-Hodgkin's lymphoma and prostate, breast, and colon cancers.
 
The company said it will use the funding to continue development of its lead drug candidate, PNT-100. ProNAi said it hopes to submit the compound to the FDA as an investigational new drug in mid-2007.
 
The current funding round includes $3.3 million that the company had previously announced from the Michigan Economic Development Corporation. Other sources for the new funding include Apjohn Ventures, Grand Angels, Amherst Fund, and Sigvion Ventures.
 
ProNAi has raised $11 million since its founding in 2004.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.